you attend the first study visit after joining the trial. during this visit, staff confirm that you meet the study criteria and collect baseline information.

baseline measurements include a lung function test called forced vital capacity (fvc), vital signs, blood and urine laboratory tests, and an electrocardiogram (ecg) to record heart activity.

after the baseline visit, you are randomly assigned to receive either azd8965 or a placebo. both are provided as a film coated tablet for oral use.

the tablet contains 00 mg of the study drug (or no active substance for the placebo) and is taken as directed by study staff, typically once each day.

the treatment period is planned to continue for 24 weeks.

you continue to take the assigned tablet daily for the duration of the study.

throughout the 24‑week period, you attend regular study visits where staff check your vital signs, repeat laboratory tests, and monitor for any side effects.

lung function (fvc) may be measured at several visits to track changes over time.

at the end of week 24, you undergo a final set of evaluations.

these include a repeat forced vital capacity (fvc) measurement, blood sampling to determine azd8965 plasma concentrations (if you received the active drug), and a full safety assessment covering vital signs, laboratory results, and any reported adverse events.

after the final assessment, the study medication is stopped and you are no longer required to attend further study visits unless a follow‑up is arranged by the study team.